“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”
Recent News
- Physiogenex to present its obese/type 2 diabetic rat models of nephropathy at 59th ERA congress in Paris, France 05/13/2022
- Physiogenex to present its obese hamster model of severe COVID-19 at Vascular Discovery 2022 in Seattle, WA, USA 05/03/2022
- Physiogenex to present its obese NASH hamster model at the International Conference on Fatty Liver 2022 (April 28-30) 04/19/2022
- Physiogenex to present at Keystone Symposia – Lessons from the pandemic in Snowbird, UT, USA 04/04/2022
- Physiogenex to present at the 31st APASL conference in Seoul, Korea (hybrid event) 03/29/2022
- Indian Pharma customer 03/22/2022